Alnylam Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc Stock

7.71P/E
€18.05BMarket capitalisation
US$19.24Earnings
—Dividend yield

Current price

—
1D
1W
1M
3M
6M
1Y
3Y
Max

Company description

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercialRNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.

Alnylam Pharmaceuticals Inc is registered in the following country: United States of America (Exchange: USNASD).

Key metrics

Key metrics and master data for the Alnylam Pharmaceuticals Inc stock.

Market capitalisation
€18.05B
P/E
7.71
P/B
5.58
P/S
4.07
P/CF
21.62
Issued shares 134M Units

Return

Here you can see the performance of the Alnylam Pharmaceuticals Inc stock.

PeriodPerfor­mance
1 Week-4.83 %
1 Month-34.23 %
3 Months-33.01 %
6 Months-43.49 %
1 Year-65.58 %
YTD-59.21 %

Dividends

With an (expected) annual dividend of —, the current stock price results in a dividend yield of —.

Dividend type—
(Expected) annual dividend —
Dividend yield —

Splits

The table shows the splits of the Alnylam Pharmaceuticals Inc share.

DateRatio
No data available.

Which ETF contains the Alnylam Pharmaceuticals Inc stock?

The Alnylam Pharmaceuticals Inc stock is contained in a total of 0 ETFs with at least 1%. You can find a list of these ETFs in the following table. With —, Alnylam Pharmaceuticals Inc has the largest weight in .

Name
Weighting
Region
Country
TER
Replication
Volume (£m)

Frequently asked questions

Here you can find all answers to your questions about the Alnylam Pharmaceuticals Inc stock.

Master data is provided by Morningstar (stocks, ETFs, funds), CoinGecko (cryptocurrencies) and Isarvest GmbH. Price data is at least 15-minute delayed exchange prices (stocks, ETFs, funds) or NAV prices (ETFs, funds). Real-time prices – where available – are provided by the providers and Lang & Schwarz (stocks, ETFs, funds) and CoinGecko (cryptocurrencies).

Isarvest GmbH assumes no liability for the information presented and cannot guarantee that the data is complete and accurate.

Affiliate notice *
Links marked with an asterisk (*) are advertising or affiliate links. If you purchase or sign up through this link, we receive compensation from the provider. This comes at no additional cost or disadvantage to you. We use this revenue to fund our free services. Thank you for your support.